HCM: Nilai perusahaan marang bathi resik HUTCHMED Ltd

HUTCHMED (HCM) has earned its status as a leading Asian innovator, although macroeconomic risks continue to weigh on its global image. The company's estimated P/E reflects market value relative to earnings, where 143.90 indicates the current level. Future prospects rely on expansion into the targeted therapy segment and the recruitment of top biologists through premium employment terms and grants.

HCM Hutchison MediPharma: Rasio rega marang bathi ing interval 04.07.2022 - 15.11.2026

Rincian analitis perusahaan HUTCHMED (China) Limited

- kuotasi lan prakiraan analis:

Bagan rega HUTCHMED Ltd|HCM - Target konsensus

- informasi kapitalisasi pasar:

Nilai pasar HUTCHMED Ltd|HCM - Nilai Total Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Aset Bersih saben Saham HUTCHMED|HCM - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Nilai Buku hutch-med.com|HCM - Total Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

- data bathi bisnis lan rasio investasi:

HCM - Penghasilan resik|Bathi resik sing dikarepake HUTCHMED (China) Limited|HCM - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi HUTCHMED (China) Limited|HCM - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Hutchison MediPharma|HCM - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku HUTCHMED|HCM - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan hutch-med.com|HCM - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep HUTCHMED (China) Limited

- indikator volume dodolan lan pendapatan:

HCM - Pendapatan lan volume dodolan|Prakiraan volume dodolan Hutchison MediPharma|HCM - Rasio rega marang pendapatan|Rega mangsa ngarep marang pendapatan HUTCHMED Corp|HCM - Wutah pendapatan YoY sajrone 12 wulan kepungkur

Analisis komprehensif perusahaan:Hutchison MediPharma

Investors must filter out speculative noise by analyzing the price-to-earnings ratio to determine the premium paid for future earnings. Global recognition of HUTCHMED (China) Limited (HCM) targeted therapies confirms the fundamental value of its assets; therefore, evaluating the company via P/E allows for a comparison of current risks against the quality of biopharmaceutical innovations, confirming the long-term resilience of the business during periods of market volatility.

Analisis perusahaan pesaing

Pangali P/E Incyte Corp|Rasio rega marang bathi Nuvation Pharma (NUVB)|Rasio rega marang bathi DAWN (Day One)|Monopar Therapeutics - Koefisien rega marang bathi|Nilai perusahaan marang bathi resik INBX|IMAB - Rasio rega marang bathi|Kapitalisasi marang bathi Fennec Pharma|Heron Therapeutics (HRTX) - Rasio rega marang bathi|Pangali rega marang bathi NVCT|CHRS (Coherus BioSciences, Inc.) - Pangali P/E|Koefisien rega marang bathi corbuspharma.com (CRBP)|Rasio rega marang bathi Cardiff Oncology, Inc. (CRDF)|BYSI - Kapitalisasi marang bathi|Rasio rega marang bathi BioAtla Corp BCAB|Lixte Biotechnology, Inc. - Rasio rega marang bathi|CTXR - Rasio rega marang bathi|Kapitalisasi marang bathi Cellectar Biosciences|BLRX: Pangali P/E|Rasio kapitalisasi marang bathi resik Can-Fite BioPharma, Ltd. CANF|Koefisien rega marang bathi APRE|Kapitalisasi marang bathi Kazia Therapeutics Limited KZIA|Koefisien rega marang bathi SLXN (Silexion Therapeutics Corp.)|NCNA (NuCana Corp) - Nilai perusahaan marang bathi resik|Chimerix, Inc. - Koefisien rega marang bathi|Rasio rega pasar marang bathi resik CYCC (Cyclacel)|G1 Therapeutics - Pangali P/E|Nilai perusahaan marang bathi resik KRON (Kronos Bio Corp)|KTRA: Pangali P/E|Kapitalisasi marang bathi oncternal.com (ONCT)|Rasio rega marang bathi Portage Biotech